BELLINI, MARTA
 Distribuzione geografica
Continente #
NA - Nord America 177
AS - Asia 149
EU - Europa 101
SA - Sud America 18
AF - Africa 8
Totale 453
Nazione #
US - Stati Uniti d'America 167
CN - Cina 58
SG - Singapore 37
IE - Irlanda 32
VN - Vietnam 23
DE - Germania 20
RU - Federazione Russa 17
BR - Brasile 14
HK - Hong Kong 13
CA - Canada 9
IN - India 7
IT - Italia 7
FI - Finlandia 6
FR - Francia 5
GB - Regno Unito 4
ZA - Sudafrica 4
PL - Polonia 3
SE - Svezia 3
BD - Bangladesh 2
CO - Colombia 2
IQ - Iraq 2
KE - Kenya 2
SA - Arabia Saudita 2
AT - Austria 1
CL - Cile 1
ES - Italia 1
GE - Georgia 1
LV - Lettonia 1
MU - Mauritius 1
MX - Messico 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
Totale 453
Città #
Dublin 32
Chandler 31
Singapore 25
Ashburn 23
Beijing 23
San Jose 20
Hong Kong 13
Dallas 12
Hanoi 10
Helsinki 6
Munich 6
Nanjing 6
Boardman 5
New York 5
Toronto 5
Gallarate 4
Ho Chi Minh City 4
Johannesburg 4
Lauterbourg 4
Lawrence 4
Los Angeles 4
Medford 4
Princeton 4
Council Bluffs 3
Da Nang 3
Falkenstein 3
Nanchang 3
Orem 3
Shanghai 3
Chennai 2
Hangzhou 2
Hebei 2
Jacksonville 2
Jiaxing 2
Montreal 2
Moscow 2
Nairobi 2
Redondo Beach 2
Tianjin 2
Warsaw 2
Wilmington 2
'Asir Region 1
Americana 1
Anta Gorda 1
Aparecida do Taboado 1
Armação dos Búzios 1
Ashgabat 1
Atlanta 1
Basra 1
Belford Roxo 1
Berezniki 1
Bismarck 1
Boston 1
Bratislava 1
Buffalo 1
Butuan 1
Caldera 1
Cartagena 1
Chandrapur 1
Changsha 1
Charleston 1
Columbus 1
Curitiba 1
Frankfurt am Main 1
Galena 1
Hyderabad 1
Jaipur 1
Jeddah 1
Jinan 1
Ji’an 1
Joinville 1
Kochi 1
Kolkata 1
Lahore 1
Langfang 1
Leawood 1
Lima 1
Linyi 1
London 1
Manaus 1
Manchester 1
Marília 1
Medellín 1
Milan 1
Mirassol 1
Morelia 1
Muscat 1
Natore 1
Ningbo 1
Nuremberg 1
Pleiku 1
Riga 1
Rio Brilhante 1
Rio Grande 1
San Francisco 1
San Giuliano Milanese 1
Santa Clara 1
Santo André 1
Shenyang 1
Shenzhen 1
Totale 355
Nome #
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 154
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 128
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 99
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 77
Totale 458
Categoria #
all - tutte 1.948
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.948


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 2 2 0 0 0 0 1 1 4 10
2022/202380 12 7 0 7 6 8 0 5 35 0 0 0
2023/202439 6 6 1 1 3 16 0 2 1 1 1 1
2024/202579 5 4 1 1 0 7 4 4 23 0 13 17
2025/2026187 12 12 16 18 18 4 47 16 26 9 5 4
Totale 458